Antagonist elicited cannabis withdrawal in humans / David A Gorelick en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 5 (Octubre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 5 (Octubre) . - PP. 603-612 Título : Antagonist elicited cannabis withdrawal in humans Tipo de documento: texto impreso Autores: David A Gorelick, Autor ; Robert S. Goodwin, Autor ; Eugene Schwilke, Autor Fecha de publicación: 2022 Artículo en la página: PP. 603-612 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antagonista, Cannabis, Marihuana, Rimonabant, Abstinencia Resumen: Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ9-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis dependence while residing on a closed research unit. Link: ./index.php?lvl=notice_display&id=29356 [artículo] Antagonist elicited cannabis withdrawal in humans [texto impreso] / David A Gorelick, Autor ; Robert S. Goodwin, Autor ; Eugene Schwilke, Autor . - 2022 . - PP. 603-612. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 5 (Octubre) . - PP. 603-612 Palabras clave: Antagonista, Cannabis, Marihuana, Rimonabant, Abstinencia Resumen: Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ9-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis dependence while residing on a closed research unit. Link: ./index.php?lvl=notice_display&id=29356

---

1 (1 - 1 / 1)